Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydromorphone versus morphine PCA for moderate to severe cancer pain
ChiCTR1900028015Phase 4Recruiting
- Sponsor
- Fuling Central Hospital
- Start
- Aug 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydromorphone and morphine in cancer pain (2 arms), sponsored by Fuling Central Hospital. Primary endpoints: Pain assessment, Anxiety score at Day 14 and 1 more. Started Aug 2019; status: recruiting.
02
Drugs
hydromorphonemorphine
03
Conditions
cancer pain
Beyond the preview
Go deeper on ChiCTR1900028015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028015.